Results 171 to 180 of about 16,542 (247)

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream improved clinical signs and symptoms in the TRuE‐AD4 study. Abstract Background In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently ...
José Manuel Carrascosa   +14 more
wiley   +1 more source

Management of chronic urticaria: Current status and future prospect

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman   +15 more
wiley   +1 more source

Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes   +6 more
wiley   +1 more source

Treatment Outcomes of Trichorrhexis Invaginata in SPINK5‐sEDD: A Systematic Review

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT This systematic review evaluates treatment outcomes for trichorrhexis invaginata in SPINK5‐sEDD, formerly known as Netherton syndrome. SPINK5‐sEDD is a rare congenital disorder defined by ichthyosiform erythroderma, trichorrhexis invaginata, and atopy.
Katya Peri   +8 more
wiley   +1 more source

Successful treatment of Hailey–Hailey disease (HHD) with the IL‐13 inhibitor lebrikizumab

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Elena Schneider   +3 more
wiley   +1 more source

Growth Assessment in Children Under 12 Years With Moderate‐to‐Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Background/Objective The multifactorial disease burden of moderate‐to‐severe atopic dermatitis (AD) may affect children's growth. We report height, weight, and body mass index (BMI) of children under 12 years old with moderate‐to‐severe AD in comparison to the general population.
Amy S. Paller   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy